Abstract
Background and Aims: Apolipoprotein A-IV (apoA-IV) is involved in reverse cholesterol transport and has anti-atherogenic, antioxidative and antithrombotic properties. A decreasing estimated glomerular filtration rate (eGFR) is associated with increasing apoA-IV concentrations. The aim of this study was to examine the association between apo-A-IV concentrations with all-cause mortality and cardiovascular outcomes in patients with chronic kidney disease (CKD).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
